## IN THE CLAIMS

Please amend the claims as follows:

杏

- 1. (Amended) A method of <u>analyzing a sample taken from a human patient who is</u> <u>asymptomatic for coronary artery disease for factors associated with coronary artery disease making an assessment of the likelihood that a human patient who is asymptomatic for coronary artery disease has the disease, the method comprising the steps:</u>
- (a) obtaining the level of an atherogenic protein in a sample from the patient, obtaining the level of an acute phase reactant in a sample from the patient, and optionally obtaining the level of an anti-atherogenic protein in a sample from the patient;
  - (b) obtaining at least one of:
- (i) a first cut-point <u>based on related to</u> the atherogenic protein and a second cut-point <u>based on related to</u> the acute phase reactant,
- (ii) a third cut-point <u>based on</u> related to the atherogenic protein and the acute phase reactant,
- (iii) a fourth cut-point <u>based on related to</u> the atherogenic protein and the acute phase reactant and a fifth cut-point <u>based on related to</u> the anti-atherogenic protein,
- (iv) a sixth cut-point <u>based on related to</u> the atherogenic protein and a seventh cut-point <u>based on related to</u> the acute phase reactant and the anti-atherogenic protein,
- (v) an eighth cut-point <u>based on related to</u> the atherogenic protein and the anti-atherogenic protein and a ninth cut-point <u>based on related to</u> the acute phase reactant,
- (vi) a tenth cut-point <u>based on</u> related to the atherogenic protein, the acute phase reactant, and the anti-atherogenic protein,
- (vii) an eleventh cut-point <u>based on related to</u> the atherogenic protein, a twelfth cut-point <u>based on related to</u> the acute phase reactant, and a thirteenth cut-point <u>based on related to</u> the anti-atherogenic protein; and
- (c) assessing whether the patient <u>has</u> is likely to have asymptomatic coronary artery disease based on at least one of the following:

- (i) a comparison to the first cut-point of a first value <u>based on related to</u> the level of the atherogenic protein and a comparison to the second cut-point of a second value <u>based on related to</u> the level of the acute phase reactant,
- (ii) a comparison to the third cut-point of a third value <u>based on</u> <del>related to</del> the levels of the atherogenic protein and acute phase reactant,
- (iii) a comparison to the fourth cut-point of a fourth value <u>based on related to</u> the levels of the atherogenic protein and acute phase reactant and a comparison to the fifth cut-point of a fifth value <u>based on related to</u> the level of the anti-atherogenic protein,
- (iv) a comparison to the sixth cut-point of a sixth value <u>based on related to</u> the level of the atherogenic protein and a comparison to the seventh cut-point of a seventh value <u>based on related to</u> the levels of the acute phase reactant and anti-atherogenic protein,
- (v) a comparison to the eighth cut-point of an eighth value <u>based on related to</u> the levels of the atherogenic protein and anti-atherogenic protein and a comparison to the ninth cut-point of a ninth value <u>based on related to</u> the level of the acute phase reactant,
- (vi) a comparison to the tenth cut-point of a tenth value <u>based on related to</u> the levels of the atherogenic protein, acute phase reactant, and anti-atherogenic protein, and
- (vii) a comparison to the eleventh cut-point of an eleventh value <u>based on</u> related to the level of the atherogenic protein, a comparison to the twelfth cut-point of a twelfth value <u>based on related to</u> the level of the acute phase reactant, and a comparison to the thirteenth cut-point of a thirteenth value <u>based on related to</u> the level of the anti-atherogenic protein.
- 2. (original) The method of claim 1 wherein the atherogenic protein comprises OxLDL (oxidized low density lipoprotein).
- 3. (original) The method of claim 2 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 (apolipoprotein B-100) moiety.

a

- 4. (original) The method of claim 1 wherein the acute phase reactant comprises a positive acute phase reactant or a negative acute phase reactant.
- 5. (original) The method of claim 4 wherein the positive acute phase reactant is selected from the group consisting of C-reactive protein, serum amyloid A, von Willebrand factor, ferritin, and fibrinogen and the negative acute phase reactant is selected from the group consisting of albumin, apo A-I (apolipoprotein A-II), and HDL (high density lipoprotein).
- 6. (original) The method of claim 1 wherein the anti-atherogenic protein comprises HDL.
- 7. (original) The method of claim 1 wherein the atherogenic protein comprises OxLDL and the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 8. (original) The method of claim 7 wherein the anti-atherogenic protein comprises HDL.
- 9. (original) The method of claim 1 wherein step (a) uses an immunological assay to obtain the level of atherogenic protein.
- 10. (cancelled)

d

11. (previously presented) The method of claim 9 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM (Belgian Coordinated Collections of Microorganisms) under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.

- 12. (original) The method of claim 1 wherein the atherogenic protein comprises an atherogenic low density lipoprotein and step (a) is conducted using an immunological assay.
- 13. (original) The method of claim 1 wherein the atherogenic protein comprises OxLDL and an immunological assay is used to obtain the level of atherogenic protein.

## 14. (cancelled)

4

- 15. (original) The method of claim 13 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 16. (original) The method of claim 13 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 17. (original) The method of claim 16 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 18. (original) The method of claim 13 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 moiety.
- 19. (original) The method of claim 18 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 20. (original) The method of claim 19 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 21. (original) The method of claim 12 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11

deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.

- 22. (Amended) A method of <u>providing</u> facilitating the assessment by a medical professional <u>with information based on a sample obtained from a human patient who is asymptomatic for coronary artery disease for the medical professional to use in <u>determining whether the individual has coronary artery disease</u> of the likelihood that a <u>human patient who is asymptomatic for coronary artery disease has the disease, the method</u> comprising the steps:</u>
- (a) obtaining the level of an atherogenic protein in a sample from the patient, obtaining the level of an acute phase reactant in a sample from the patient, and optionally obtaining the level of an anti-atherogenic protein in a sample from the patient;
  - (b) obtaining at least one of:

- (i) a first cut-point <u>based on related to</u> the atherogenic protein and a second cut-point related to the acute phase reactant,
- (ii) a third cut-point <u>based on related to</u> the atherogenic protein and the acute phase reactant,
- (iii) a fourth cut-point <u>based on related to</u> the atherogenic protein and the acute phase reactant and a fifth cut-point <u>based on related to</u> the anti-atherogenic protein,
- (iv) a sixth cut-point <u>based on related to</u> the atherogenic protein and a seventh cut-point <u>based on related to</u> the acute phase reactant and the anti-atherogenic protein,
- (v) an eighth cut-point <u>based on related to</u> the atherogenic protein and the anti-atherogenic protein and a ninth cut-point <u>based on related to</u> the acute phase reactant,
- (vi) a tenth cut-point <u>based on related to</u> the atherogenic protein, the acute phase reactant, and the anti-atherogenic protein, and
- (vii) an eleventh cut-point <u>based on</u> related to the atherogenic protein, a twelfth cut-point <u>based on</u> related to the acute phase reactant, and a thirteenth cut-point <u>based on related to</u> the anti-atherogenic protein;
  - (c) providing to the medical professional at least one of:

- (i) a first value <u>based on related to</u> the level of the atherogenic protein and a second value <u>based on related to</u> the level of the acute phase reactant,
- (ii) a third value <u>based on related to</u> the levels of the atherogenic protein and acute phase reactant,
- (iii) a fourth value <u>based on related to</u> the levels of the atherogenic protein and acute phase reactant and a fifth value <u>based on related to</u> the level of the anti-atherogenic protein,
- (iv) a sixth value <u>based on related to</u> the level of the atherogenic protein and a seventh value <u>based on related to</u> the levels of the acute phase reactant and anti-atherogenic protein,
- (v) an eighth value <u>based on related to</u> the levels of the atherogenic protein and anti-atherogenic protein and a ninth value <u>based on related to</u> the level of the acute phase reactant, and
- (vi) a tenth value <u>based on related to</u> the levels of the atherogenic protein, acute phase reactant, and anti-atherogenic protein,
- (vii) an eleventh value <u>based on related to</u> the level of the atherogenic protein, a twelfth value <u>based on related to</u> the level of the acute phase reactant, and a thirteenth value <u>based on related to</u> the level of the anti-atherogenic protein; and
- (d) providing to the medical professional the appropriate one or more of the cut-points to permit the medical professional to assess whether the patient <u>has</u> is likely to have asymptomatic coronary artery disease based on at least one of the following:
- (i) a comparison to the first cut-point of the first value and a comparison to the second cut-point of the second value,
  - (ii) a comparison to the third cut-point of the third value,
- (iii) a comparison to the fourth cut-point of the fourth value and a comparison to the fifth cut-point of the fifth value,
- (iv) a comparison to the sixth cut-point of the sixth value and a comparison to the seventh cut-point of the seventh value,
- (v) a comparison to the eighth cut-point of the eighth value and a comparison to the ninth cut-point of the ninth value,
  - (vi) a comparison to the tenth cut-point of the tenth value, and

- (vii) a comparison to the eleventh cut-point of the eleventh value, a comparison to the twelfth cut-point of the twelfth value, and a comparison to the thirteenth cut-point of the thirteenth value.
- 23. (original) The method of claim 22 wherein the atherogenic protein comprises OxLDL.
- 24. (original) The method of claim 23 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 moiety.
- 25. (original) The method of claim 22 wherein the acute phase reactant comprises a positive acute phase reactant or a negative acute phase reactant.
- 26. (original) The method of claim 25 wherein the positive acute phase reactant is selected from the group consisting of C-reactive protein, serum amyloid A, von Willebrand factor, ferritin, and fibrinogen and the negative acute phase reactant is selected from the group consisting of albumin, apo A-I, apo A-II, and HDL.
- 27. (original) The method of claim 22 wherein the anti-atherogenic protein comprises HDL.
- 28. (original) The method of claim 22 wherein the atherogenic protein comprises OxLDL and the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 29. (original) The method of claim 28 wherein the anti-atherogenic protein is HDL.
- 30. (original) The method of claim 22 wherein step (a) uses an immunological assay to obtain the level of atherogenic protein.
- 31. (cancelled)

.;

- 32. (original) The method of claim 30 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.
- 33. (original) The method of claim 22 wherein the atherogenic protein comprises an atherogenic low density lipoprotein and step (a) is conducted using an immunological assay.
- 34. (original) The method of claim 22 wherein the atherogenic protein comprises OxLDL and an immunological assay is used to obtain the level of atherogenic protein.
- 35. (cancelled)

.;

- 36. (original) The method of claim 34 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 37. (original) The method of claim 34 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 38. (original) The method of claim 37 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 39. (original) The method of claim 34 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 moiety.

- 40. (original) The method of claim 39 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 41. (original) The method of claim 40 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 42. (original) The method of claim 33 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.
- 43. (withdrawn) A method of making an assessment of the likelihood that a human patient has a stage of coronary artery disease, the method comprising the steps:
- (a) obtaining the level of an atherogenic protein in a sample from the patient, obtaining the level of an acute phase reactant in a sample from the patient, and optionally obtaining the level of an anti-atherogenic protein in a sample from the patient;
  - (b) obtaining at least one of:

4

- (i) a first cut-point related to the atherogenic protein and a second cut-point related to the acute phase reactant,
- (ii) a third cut-point related to the atherogenic protein and the acute phase reactant,
- (iii) a fourth cut-point related to the atherogenic protein and the acute phase reactant and a fifth cut-point related to the anti-atherogenic protein,
- (iv) a sixth cut-point related to the atherogenic protein and a seventh cut-point related to the acute phase reactant and the anti-atherogenic protein,
- (v) an eighth cut-point related to the atherogenic protein and the anti-atherogenic protein and a ninth cut-point related to the acute phase reactant,

- (vi) a tenth cut-point related to the atherogenic protein, the acute phase reactant, and the anti-atherogenic protein,
  - (vii) an eleventh cut-point related to the atherogenic protein, a twelfth cut-point related to the acute phase reactant, and a thirteenth cut-point related to the anti-atherogenic protein; and
- (c) assessing whether the patient is likely to have a stage of coronary artery disease based on at least one of the following:
- (i) a comparison to the first cut-point of a first value related to the level of the atherogenic protein and a comparison to the second cut-point of a second value related to the level of the acute phase reactant,
- (ii) a comparison to the third cut-point of a third value related to the levels of the atherogenic protein and acute phase reactant,
- (iii) a comparison to the fourth cut-point of a fourth value related to the levels of the atherogenic protein and acute phase reactant and a comparison to the fifth cut-point of a fifth value related to the level of the anti-atherogenic protein,
- (iv) a comparison to the sixth cut-point of a sixth value related to the level of the atherogenic protein and a comparison to the seventh cut-point of a seventh value related to the levels of the acute phase reactant and anti-atherogenic protein,
- (v) a comparison to the eighth cut-point of an eighth value related to the levels of the atherogenic protein and anti-atherogenic protein and a comparison to the ninth cut-point of a ninth value related to the level of the acute phase reactant,
- (vi) a comparison to the tenth cut-point of a tenth value related to the levels of the atherogenic protein, acute phase reactant, and anti-atherogenic protein, and
- (vii) a comparison to the eleventh cut-point of an eleventh value related to the level of the atherogenic protein, a comparison to the twelfth cut-point of a twelfth value related to the level of the acute phase reactant, and a comparison to the thirteenth cut-point of a thirteenth value related to the level of the anti-atherogenic protein.
- 44. (withdrawn) The method of claim 43 wherein the atherogenic protein comprises OxLDL (oxidized low density lipoprotein).

.;

- 45. (withdrawn) The method of claim 44 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 (apolipoprotein B-100) moiety.
- 46. (withdrawn) The method of claim 43 wherein the acute phase reactant comprises a positive acute phase reactant or a negative acute phase reactant.
- 47. (withdrawn) The method of claim 46 wherein the positive acute phase reactant is selected from the group consisting of C-reactive protein, serum amyloid A, von Willebrand factor, ferritin, and fibrinogen and the negative acute phase reactant is selected from the group consisting of albumin, apo A-I (apolipoprotein A-I), apo A-II (apolipoprotein A-II), and HDL (high density lipoprotein).
- 48. (withdrawn) The method of claim 43 wherein the anti-atherogenic protein comprises HDL.
- 49. (withdrawn) The method of claim 43 wherein the atherogenic protein comprises OxLDL and the acute phase reactant is selected from the group consisting of C-reactive protein and fibringen.
- 50. (withdrawn) The method of claim 49 wherein the anti-atherogenic protein comprises HDL.
- 51. (withdrawn) The method of claim 43 wherein step (a) uses an immunological assay to obtain the level of atherogenic protein.
- 52. (withdrawn) The method of claim 51 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM (Belgian Coordinated Collections of Microorganisms) under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under

. ;

deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.

- 53. (withdrawn) The method of claim 43 wherein the atherogenic protein comprises an atherogenic low density lipoprotein and step (a) is conducted using an immunological assay.
- 54. (withdrawn) The method of claim 43 wherein the atherogenic protein comprises OxLDL and an immunological assay is used to obtain the level of atherogenic protein.
- 55. (withdrawn) The method of claim 54 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 56. (withdrawn) The method of claim 54 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 57. (withdrawn) The method of claim 56 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 58. (withdrawn) The method of claim 54 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 moiety.
- 59. (withdrawn) The method of claim 58 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 60. (withdrawn) The method of claim 59 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibringen.
- 61. (withdrawn) The method of claim 53 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM under deposit

accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.

- 62. (withdrawn) The method of claim 43 wherein the stage of coronary artery disease is stable angina.
- 63. (withdrawn) The method of claim 43 wherein the stage of coronary artery disease is an acute coronary syndrome.
- 64. (withdrawn) The method of claim 63 wherein the stage of coronary artery disease is unstable angina.
- 65. (withdrawn) The method of claim 63 wherein the stage of coronary artery disease is acute myocardial infarction.
- 66. (withdrawn) A method of facilitating the assessment by a medical professional of the likelihood that a human patient has a stage of coronary artery disease, the method comprising the steps:
- (a) obtaining the level of an atherogenic protein in a sample from the patient, obtaining the level of an acute phase reactant in a sample from the patient, and optionally obtaining the level of an anti-atherogenic protein in a sample from the patient;
  - (b) obtaining at least one of:
- (i) a first cut-point related to the atherogenic protein and a second cut-point related to the acute phase reactant,
- (ii) a third cut-point related to the atherogenic protein and the acute phase reactant,
- (iii) a fourth cut-point related to the atherogenic protein and the acute phase reactant and a fifth cut-point related to the anti-atherogenic protein,

. ;

- (iv) a sixth cut-point related to the atherogenic protein and a seventh cut-point related to the acute phase reactant and the anti-atherogenic protein,
- (v) an eighth cut-point related to the atherogenic protein and the anti-atherogenic protein and a ninth cut-point related to the acute phase reactant,
- (vi) a tenth cut-point related to the atherogenic protein, the acute phase reactant, and the anti-atherogenic protein, and
- (vii) an eleventh cut-point related to the atherogenic protein, a twelfth cut-point related to the acute phase reactant, and a thirteenth cut-point related to the anti-atherogenic protein;
  - (c) providing to the medical professional at least one of:
- (i) a first value related to the level of the atherogenic protein and a second value related to the level of the acute phase reactant,
- (ii) a third value related to the levels of the atherogenic protein and acute phase reactant,
- (iii) a fourth value related to the levels of the atherogenic protein and acute phase reactant and a fifth value related to the level of the anti-atherogenic protein,
- (iv) a sixth value related to the level of the atherogenic protein and a seventh value related to the levels of the acute phase reactant and anti-atherogenic protein,
- (v) an eighth value related to the levels of the atherogenic protein and anti-atherogenic protein and a ninth value related to the level of the acute phase reactant, and
- (vi) a tenth value related to the levels of the atherogenic protein, acute phase reactant, and anti-atherogenic protein,
- (vii) an eleventh value related to the level of the atherogenic protein, a twelfth value related to the level of the acute phase reactant, and a thirteenth value related to the level of the anti-atherogenic protein; and
- (d) providing to the medical professional the appropriate one or more of the cut-points to permit the medical professional to assess whether the patient is likely to have a stage of coronary artery disease based on at least one of the following:
- (i) a comparison to the first cut-point of the first value and a comparison to the second cut-point of the second value,

- (ii) a comparison to the third cut-point of the third value,
- (iii) a comparison to the fourth cut-point of the fourth value and a comparison to the fifth cut-point of the fifth value,
- (iv) a comparison to the sixth cut-point of the sixth value and a comparison to the seventh cut-point of the seventh value,
- (v) a comparison to the eighth cut-point of the eighth value and a comparison to the ninth cut-point of the ninth value,
  - (vi) a comparison to the tenth cut-point of the tenth value, and
- (vii) a comparison to the eleventh cut-point of the eleventh value, a comparison to the twelfth cut-point of the twelfth value, and a comparison to the thirteenth cut-point of the thirteenth value.
- 67. (withdrawn) The method of claim 66 wherein the atherogenic protein comprises OxLDL.
- 68. (withdrawn) The method of claim 67 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 moiety.
- 69. (withdrawn) The method of claim 66 wherein the acute phase reactant comprises a positive acute phase reactant or a negative acute phase reactant.
- 70. (withdrawn) The method of claim 69 wherein the positive acute phase reactant is selected from the group consisting of C-reactive protein, serum amyloid A, von Willebrand factor, ferritin, and fibrinogen and the negative acute phase reactant is selected from the group consisting of albumin, apo A-I, apo A-II, and HDL.
- 71. (withdrawn) The method of claim 66 wherein the anti-atherogenic protein comprises HDL.

- 72. (withdrawn) The method of claim 66 wherein the atherogenic protein comprises OxLDL and the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 73. (withdrawn) The method of claim 72 wherein the anti-atherogenic protein is HDL.
- 74. (withdrawn) The method of claim 66 wherein step (a) uses an immunological assay to obtain the level of atherogenic protein.
- 75. (withdrawn) The method of claim 74 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.
- 76. (withdrawn) The method of claim 66 wherein the atherogenic protein comprises an atherogenic low density lipoprotein and step (a) is conducted using an immunological assay.
- 77. withdrawn) The method of claim 66 wherein the atherogenic protein comprises OxLDL and an immunological assay is used to obtain the level of atherogenic protein.
- 78. (withdrawn) The method of claim 77 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 79. (withdrawn) The method of claim 77 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.

- 80. (withdrawn) The method of claim 79 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 81. (withdrawn) The method of claim 77 wherein the OxLDL contains at least 60 substituted lysine residues per apo B-100 moiety.
- 82. (withdrawn) The method of claim 81 wherein in step (a) the level of anti-atherogenic protein is obtained and the anti-atherogenic protein comprises HDL.
- 83. (withdrawn) The method of claim 82 wherein the acute phase reactant is selected from the group consisting of C-reactive protein and fibrinogen.
- 84. (withdrawn) The method of claim 76 wherein the immunological assay uses at least one of the following monoclonal antibodies to obtain the level of atherogenic protein: mAb-4E6 produced by hybridoma Hyb4E6 deposited with the BCCM under deposit accession number LMBP 1660 CB, mAb-1H11 produced by hybridoma Hyb1H11 deposited with the BCCM under deposit accession number LMBP 1659 CB, and mAb-8A2 produced by hybridoma Hyb8A2 deposited with the BCCM under deposit accession number LMBP 1661 CB.
- 85. (withdrawn) The method of claim 66 wherein the stage of coronary artery disease is stable angina.
- 86. (withdrawn) The method of claim 66 wherein the stage of coronary artery disease is an acute coronary syndrome.
- 87. (withdrawn) The method of claim 86 wherein the stage of coronary artery disease is unstable angina.
- 88. (withdrawn) The method of claim 86 wherein the stage of coronary artery disease is acute myocardial infarction.

٠;